Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PELP1 divergent transcript (PELP1-DT, also known as lnc-EST885) is a long non-coding RNA located at chromosome 17:4704095-4705770 (hg38) near the PELP1 gene[5]. It is catalogued in major gene annotation resources but currently has no well-documented biological function or disease association. As a lncRNA, its potential functions could include regulation of neighboring gene expression or broader chromatin-associated activities[4][6], but no experimental data exist in the scientific literature to confirm such functions for PELP1-DT specifically. There are no known drug interactions, disease associations, or biomarker usage reported for this transcript. PELP1-DT should not be confused with PELP1 (Proline, glutamate and leucine rich protein 1), which is a protein-coding gene serving as a coregulator of nuclear receptors and having important roles in cancer and other biological pathways[1][3][7]. The current lack of biological or clinical information for PELP1-DT means it cannot be considered a therapeutic target at this time. Aliases such as lnc-EST885 all refer to the same lncRNA entry[5].
None known.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PELP1 divergent transcript (PELP1-DT).